Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B.

Our findings from the cirrhosis subgroup analysis using REACH-B suggest a particular benefit of treatment with TAF or TDF in non-cirrhotic patients, who had a low SIR that was highly significant ( p <0.001); for the subgroup of patients with cirrhosis, the SIR was low but did not reach statistical significance ( p = 0.15).

also in 111,027 other papers

11 , 12 , 23 , 32 Although initial treatment with TAF produced a highly significant SIR while initial treatment with TDF did not produce a significant SIR, the rollover of TDF-treated patients into OL TAF treatment at Weeks 96 and 144 does not allow for a definitive, direct comparison of the two agents.

also in 132,142 other papers